共 50 条
- [31] A randomized, phase I/II trial of AMG 102 or AMG 479 in combination with panitumumab (pmab) compared with pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Safety and efficacy results.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)Van Cutsem, E.Eng, C.Tabernero, J.Nowara, E.Swieboda-Sadlej, A.Tebbutt, N. C.Mitchell, E. P.Davidenko, I.Chen, L.Smethurst, D.
- [32] Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)Cancer Chemotherapy and Pharmacology, 2016, 78 : 585 - 593Takao TakahashiYasunori EmiEiji OkiKazuma KobayashiAkihito TsujiMototsugu ShimokawaTakaho TanakaYoshito AkagiYutaka OgataHideo BabaKazuhiro YoshidaShoji NatsugoeYoshihiko Maehara
- [33] Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 585 - 593Takahashi, TakaoEmi, YasunoriOki, EijiKobayashi, KazumaTsuji, AkihitoShimokawa, MototsuguTanaka, TakahoAkagi, YoshitoOgata, YutakaBaba, HideoYoshida, KazuhiroNatsugoe, ShojiMaehara, Yoshihiko
- [34] A phase II trial of cetuximab/irinotecan every 2 weeks in patients with metastatic colorectal cancer (CRC) that expresses wild-type KRAS after failure to first-line therapy with an irinotecan-containing regimen with or without detectable epidermal growth factor receptor (EGFR) expression.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Hong, Y.Tang, M.Kim, S.Baek, J.Lee, J.Chang, H.Jang, S.Kang, Y.Kim, T.
- [35] A blinded placebo (P)-controlled phase I/II dose-escalation study (DES) of brivanib (B), an oral selective dual inhibitor of FGF and VEGF signaling, in combination with cetuximab (C) and irinotecan (I) in patients (pts) with KRAS wild-type (KWT) advanced or metastatic colorectal cancer (annCRC): Safety tolerability, and pharmacokinetics (PK) findings.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Park, Y.El-Khoueiry, A. B.Gracian, A. C.Pfeifer, P.Chacon, M.Amadori, D.Fokstuen, T.Chemidlin, J.Kollia, G.Nuyten, D. S.
- [36] FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG studyANNALS OF ONCOLOGY, 2013, 24 (07) : 1769 - 1777Brodowicz, T.Ciuleanu, T. E.Radosavljevic, D.Shacham-Shmueli, E.Vrbanec, D.Plate, S.Mrsic-Krmpotic, Z.Dank, M.Purkalne, G.Messinger, D.Zielinski, C. C.
- [37] PEAK (study 20070509): A randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild-type (WT) KRAS metastatic colorectal cancer (mCRC)JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)Steven Schwartzberg, LeeRivera, FernandoKarthaus, MeinolfFasola, GianpieroCanon, Jean-LucYu, HuaGo, William Y.
- [38] Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patientsEUROPEAN JOURNAL OF CANCER, 2013, 49 : S8 - S9Stintzing, S.Jung, A.Rossius, L.Modest, D. P.von Weikersthal, L. FischerDecker, T.Moehler, M.Scheithauer, W.Kirchner, T.Heinemann, V.
- [39] LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Kim, Sung-BaeTan, Antoinette R.Im, Seock-AhVillanueva, RafaelValero, VicenteSaura, CristinaOliveira, MafaldaIsakoff, Steven J.Singel, Stina MuiDent, Rebecca Alexandra
- [40] A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapyJOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Ciombor, Kristen KeonEdenfield, William JefferyHubbard, Joleen MarieO'Dwyer, Peter J.Becerra, CarlosLarson, TimSpira, Alexander I.Grothey, AxelManoharan, DivyaLi, WeiLi, YouzhiBorodyansky, LauraLi, ChiangBekaii-Saab, Tanios S.